Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.64 | -0.08 | -0.03 |
| FCF Yield | -33.32% | 49.05% | 77.01% | 97.30% |
| EV / EBITDA | -4.15 | -5.04 | -4.58 | -4.47 |
| Quality | ||||
| ROIC | 1.92% | 0.91% | 1.61% | 1.97% |
| Gross Margin | 59.01% | 61.09% | 62.40% | 62.48% |
| Cash Conversion Ratio | 1.39 | 1.33 | 1.83 | 1.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.24% | -2.43% | 2.57% | 1.01% |
| Free Cash Flow Growth | -166.64% | -48.95% | -15.87% | 129.74% |
| Safety | ||||
| Net Debt / EBITDA | -4.66 | -5.66 | -5.36 | -5.28 |
| Interest Coverage | 136.20 | 63.19 | 127.98 | 181.86 |
| Efficiency | ||||
| Inventory Turnover | 2.32 | 2.32 | 2.29 | 2.50 |
| Cash Conversion Cycle | 170.23 | 176.67 | 175.37 | 167.51 |